Polpharma has struck a global licensing deal for its proposed biosimilar rival to Biogen’s Tysabri (natalizumab) with Sandoz through its Polpharma Biologics division. The worldwide agreement gives the Novartis subsidiary commercialization rights to the biosimilar natalizumab for treating relapsing-remitting multiple sclerosis, which is currently in Phase III trials.
“Under the agreement,” Sandoz outlined, “Polpharma Biologics will maintain responsibilities for development, manufacturing and supply of the proposed biosimilar natalizumab.”...
